Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization

Virology

Volumn 238, Issue 2, 1997, Pages 254-264

  Zhang, Yi Jun ^a   Fredriksson, Robert ^a   McKeating, Jane A ^b   Fenyö, Eva Maria ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOID CELL LINE; MOLECULAR CLONING; MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION;

EID: 0031585555     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8812     Document Type: Article

References (41)

1. Albert J., Fenyö E. M. Simple, sensitive and specific detection of HIV-1 in clinical specimens by polymerase chain reaction with nested primers. J. Clin. Microbiol. 28:1990;1560-1564.
2. Åsjö B., Morfeldt-Månson L., Albert J., Biberfeld G., Karlsson A., Lidman K., Fenyö E. M. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. ii:1986;660-662.
3. Back N. K. T., Smit L., De Jong J. J., Keulen W., Schutten M., Goudsmit J., Tersmette M. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology. 199:1994;431-438.
4. Baldinotti F., Matteucci D., Mazzetti P., Giannelli C., Bandecchi P., Tozzini F., Bendinelli M. Neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J. Virol. 68:1994;4572-4579.
5. Benjouad A., Gluckman J. C., Rochat H., Montagnier L., Bahraoui E. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency cirus type 1 recombinant gp160. J. Virol. 66:1992;2473-2483.
6. Bou-Habib D. C., Roderiquez G., Oravecz T., Berman P. W., Lusso P., Norcross M. A. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:1994;6006-6013.
7. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., Gruber G., Tauer C., Steinndl F., Jungbauer A. Electrofusion and EBV transformation for PBL immortalisation: generation of human monoclonal antibodies against HIV-1 proteins. AIDS Res. Hum. Retroviruses. 10:1994;359-369.
8. Cheng-Mayer C., Seto D., Levy J. A. Altered host range of HIV-1 after passage through various human cell types. Virology. 181:1991;288-294.
9. Cohen J. Jitters jeopardize AIDS vaccine trials. Science. 262:1993;980-981.
10. Cordell J., Moore J. P., Dean C. F., Klasse P. J., Weiss R. A., McKeating J. A. Rat monoclonal antibodies to non-overlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology. 185:1991;72-79.
11. Fenyö E. M., Morfeldt-Månson L., Chiodi F., Lind B., von Gegerfelt A., Albert J., Olausson E., Åsjö B. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J. Virol. 62:1988;4414-4419.
12. Fouts T. R., Binley J. M., Trkola A., Robinson J. E., Moore J. P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:1997;2779-2785.
13. Fredriksson R., Stålhandske P., von Gegerfelt A., Lind B., Åman P., Rassart E., Fenyö E. Biological characterization of infectious molecular clones derived from a human immunodeficiency virus type-1 isolate with rapid/high replicative capacity. Virology. 181:1991;55-61.
14. Goochee C. F., Monica T. Environmental effects on protein glycosylation. Bio/Technology. 8:1990;421-427.
15. Gorny M. K., Xu J. Y., Gianakakos V., Zolla-Pazner S. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 86:1989;1624-1628.
16. Ho D., McKeating J., Li X., Moudgil T., Daar E., Sun N., Robinson J. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:1991;489-493.
17. Kabat D., Kozak S. L., Wehrly K., Chesebro B. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of humam immunodeficiency virus type 1. J. Virol. 68:1994;2570-2577.
18. Koot M., Vos A. H. V., Keet R. P. M., de Goede R. E. Y., Dercksen W., Terpstra F. G., Coutinho R. A., Miedema F., Tersmette M. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS. 6:1992;49-54.
19. Kostrikis L. G., Cao Y., Ngai H., Moore J. P., Ho D. D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70:1996;445-458.
20. Lee W.-R., Syu W.-J., Du B., Matsuda M., Tan S., Wolf A., Essex M., Lee T.-H. Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 89:1992;2213-2217.
21. Mascola J. R., Louwagie J., McCutchan F. E., Fischer C. L., Hegerich P. A., Wagner K. F., Fowler A. K., McNeil J. G., Burke D. S. Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype. J. Infect. Dis. 169:1994;48-54.
22. McKeating J. A., Zhang Y. J., Arnold C., Fredriksson R., Fenyö E. M., Balfe P. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficienct virus type 1 show increased sensitivity to neutralization by human sera. Virology. 220:1996;450-460.
23. Moore J. P., Burkly L. C., Connor R. L., Cao Y., Tizard R., Ho D. D., Fisher R. A. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the response of their envelope glycoproteins to soluble CD4. AIDS Res. Hum. Retroviruses. 9:1993;529-539.
24. Moore J. P., Cao Y., Quing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. III, Burton D. R., Ho D. D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:1995;101-109.
25. Moore J. P., Ho D. D. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS. 9:1995;S117-S136.
26. Nyambi P. N., Nkengasong J., Lewi P., Andries K., Janssens W., Fransen K., Heyndrichx L., Piot P., van der Groen G. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70:1996;6235-6243.
27. Parren P. W. H. I., Fisicaro P., Labrijn A. F., Binley J. M., Yang W.-P., Ditzel H. J., Barbas C. F. III, Burton E. R. In vitro antigen challenge of human antibody libraries for vaccine evaluation: The human immunodeficiency virus type 1 envelope. J. Virol. 70:1996;9046-9050.
28. LAIMALELI. Virology. 185:1991;661-672.
29. Sattentau Q. J., Moore J. P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:1995;185-196.
30. Sawyer L. S. W., Wrin M. T., Crawford-Miksza L., Potts B., Wu Y., Weber P. A., Alfonso R. D., Hanson C. V. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68:1994;1342-1349.
31. Schonning K., Jansson B., Olofsson S., Hansen J.-E. S. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies derected against the V3 loop of human immunodeficiency virus type 1. J. Gen. Virol. 77:1996;753-758.
32. Stamatatos L., Cheng-Mayer C. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69:1995;6191-6198.
33. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. Replicative function and neutralisation sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:1995;4413-4422.
34. Sundqvist V. A., Albert J., Ohlsson E., Hinkula J., Fenyö E. M., Wahren B. Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J. Med. Virol. 29:1989;170-175.
35. Tan W., Fredriksson R., Björndal Å., Balfe P., Fenyö E. M. Cotransfection of HIV-1 molecular clones with restricted cell tropism may yield progeny virus with altered phenotype. AIDS Res. Hum. Retroviruses. 9:1993;321-329.
36. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J. P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficienct virus type 1. J. Virol. 70:1996;1100-1108.
37. Turner S., Tizard R., DeMarinis J., Pepinsky R. B., Zullo J., Schooley R., Fisher R. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 89:1992;1335-1339.
38. Weber J., Fenyö E. M., Beddows S., Kaleebu P., Björndal Å. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J. Virol. 70:1996;7827-7832.
39. Willey R. L., Shibata R., Freed E. O., Cho M. W., Martin M. A. Differential glycosylation, viron incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures. J. Virol. 70:1996;6431-6436.
40. Wrin T., Loh T. P., Charron Vennari J., Schuitemaker H., Nunberg J. H. Adaptation to parsistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:1995;39-48.
41. Zhang Y.-J., Putkonen P., Albert J., Öhman P., Biberfeld G., Fenyö E. M. Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques. Virology. 200:1994;583-589.